WallStSmart

AstraZeneca PLC (AZN)vsNovo Nordisk A/S (NVO)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 435% more annual revenue ($333.65B vs $62.38B). NVO leads profitability with a 33.9% profit margin vs 17.7%. AZN appears more attractively valued with a PEG of 1.35. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

NVO

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 10.0Value: 5.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+11.8%)

Margin of Safety

+11.8%

Fair Value

$197.76

Current Price

$174.35

$23.41 discount

UndervaluedFair: $197.76Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

NVO6 strengths · Avg: 9.8/10
P/E RatioValuation
10.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
52.0%10/10

Every $100 of equity generates 52 in profit

Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
40.1%10/10

Strong operational efficiency at 40.1%

Free Cash FlowQuality
$28.10B10/10

Generating 28.1B in free cash flow

Market CapQuality
$177.74B9/10

Large-cap with strong market position

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

NVO3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.482/10

Expensive relative to growth rate

EPS GrowthGrowth
-15.8%2/10

Earnings declined 15.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

NVO carries more volatility with a beta of 0.37 — expect wider price swings.

AZN is growing revenue faster at 6.7% — sustainability is the question.

NVO generates stronger free cash flow (28.1B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (68/100 vs 59/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?